Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)

This study — called LAYOVER — is testing whether targeted local treatments (like radiation or ablation) applied to a small number of new or progressing cancer sites can help people with urological cancers (prostate, bladder, or kidney cancer) stay on their current systemic treatment longer, rather than switching treatments. **You may be eligible if...** - You are 18 years or older - You have confirmed prostate cancer, urothelial (bladder) carcinoma, or renal (kidney) cell carcinoma - You are currently on systemic therapy that is mostly controlling your cancer - You have had at least one prior treatment line with at least 3 months of clinical benefit - You have 5 or fewer new or progressing cancer spots that can be safely treated with local ablative therapy **You may NOT be eligible if...** - You have medical conditions preventing safe use of ablative therapies (such as radiation or ablation) - You have treatment-related side effects that limit further local therapy - You have cancer spots growing inside the brain (intracranial progression) Talk to your doctor to see if this trial is right for you.